Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Publishes Data on RNAi Technology in Cancer


Dicerna Pharmaceuticals this week announced the publication of data by company researchers and collaborators demonstrating the potential therapeutic benefit of knocking down a key cancer target using RNAi.

Appearing in Molecular Therapy, the paper shows that Dicerna's Dicer-substrate molecules, when devliered using its proprietary lipid nanoparticles, can significantly reduce the expression of beta-catenin in liver cancer models.

Further, treatment reduced animals' tumor burden, either alone or in combination with chemotherapy.

“These data provide important proof of concept for Dicerna’s approach … to silence traditionally undruggable cancer targets,” Dicerna CSO Bob Brown said in a statement.

Dicerna is currently preparing to begin clinical testing of a Dicer-substrate-based hepatocellular cancer treatment drug, which targets Myc, in 2014.